CytomX Therapeutics (NASDAQ:CTMX) Given Neutral Rating at HC Wainwright

CytomX Therapeutics (NASDAQ:CTMX)‘s stock had its “neutral” rating reiterated by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports.

CytomX Therapeutics Price Performance

Shares of NASDAQ CTMX opened at $0.66 on Friday. The business has a 50-day moving average of $0.84 and a two-hundred day moving average of $1.02. The company has a market capitalization of $52.03 million, a price-to-earnings ratio of 3.91 and a beta of 1.05. CytomX Therapeutics has a 1 year low of $0.60 and a 1 year high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last posted its earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.45. The firm had revenue of $38.09 million during the quarter, compared to analysts’ expectations of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. As a group, equities research analysts expect that CytomX Therapeutics will post -0.05 earnings per share for the current year.

Institutional Investors Weigh In On CytomX Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. grew its holdings in shares of CytomX Therapeutics by 1.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 16,359 shares during the last quarter. Northern Trust Corp boosted its position in shares of CytomX Therapeutics by 16.0% in the 4th quarter. Northern Trust Corp now owns 150,632 shares of the biotechnology company’s stock valued at $155,000 after purchasing an additional 20,746 shares during the period. Miller Financial Services LLC purchased a new position in CytomX Therapeutics during the 4th quarter worth approximately $26,000. Connor Clark & Lunn Investment Management Ltd. increased its position in CytomX Therapeutics by 10.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock worth $331,000 after buying an additional 26,373 shares during the period. Finally, Prudential Financial Inc. lifted its stake in CytomX Therapeutics by 76.2% in the fourth quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 27,800 shares during the last quarter. 67.77% of the stock is owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.